A Phase 2 interventional study of GSK3036656 and Bedaquiline in Tuberculosis, sponsored by GlaxoSmithKline. Completed at 1 site in South Africa. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-17.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing bedaquiline in Tuberculosis, Pulmonary — 5 open to participants now, 8 under way, 5 of them phase 3. bedaquiline · Tuberculosis, Pulmonary.
Among the 22 studies testing bedaquiline in Tuberculosis, Pulmonary, this one is the 13th largest by enrollment, is one of 2 that started in 2022, is one of 10 in phase 2, and was the 13th registered.
319 studies on the registry are indexed under Tuberculosis, Pulmonary; 71 are open to participants now.
Browse Tuberculosis, Pulmonary studies →5 of the 22 studies testing bedaquiline in Tuberculosis, Pulmonary are open now, in 9 countries. Recruiting first, the newest first:
University of California, San Francisco · Sites in Mongolia, Pakistan, Peru and 2 more countries
Ages 14+
Shenzhen Third People's Hospital · Sites in China
Ages 18–65
University College, London · Sites in Moldova, South Africa, Tanzania and 2 more countries
Ages 18+
Shanghai Pulmonary Hospital, Shanghai, China
Ages 18–60
Shenzhen Third People's Hospital
Ages 65+
By country, each count listing its studies:
bedaquiline: first FDA approval 2012 (SIRTURO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 46 Tuberculosis, Pulmonary studies recruiting now, 22 (48%) set no upper age limit and 20 (43%) stop at 75 or younger; 11 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 16 · Phase 3 12
First in 2010; this study’s year is marked. 2 started in 2022.
This study's enrollment of 127 is below the median of 146 across 227 interventional studies indexed under Tuberculosis, Pulmonary.
Median enrollment 235 across the 22 interventional studies. Of the 13 that completed or were terminated, 8 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 22 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
GlaxoSmithKline has 2 studies filed under Tuberculosis, Pulmonary — fewer than ten, so there is no comparison to draw.
4 of the studies testing bedaquiline in Tuberculosis, Pulmonary that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05766267Phase 3Centers for Disease Control and PreventionShort-course Regimens for the Treatment of Pulmonary Tuberculosis | 2026-12-31 |
| NCT06649721Phase 3Huashan HospitalInnovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis:BDLL Chinese Cohort | 2027-02-28 |
| NCT07129629Shanghai Pulmonary Hospital, Shanghai, ChinaShort-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis | 2026-12-31 |
| NCT06114628University College, LondonPlatform Assessing Regimens and Durations In a Global Multisite Consortium for TB | 2027-02-24 |
Add all 4 to your calendar (.ics) → With an account.
Among the 22 studies testing bedaquiline in Tuberculosis, Pulmonary, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study measured the early bactericidal activity (EBA), safety, tolerability and pharmacokinetics of GSK3036656 in combination with either delamanid, bedaquiline or BTZ-043 and delamanid in combination with bedaquiline or standard of care, for 14 days, in participants with newly diagnosed sputum smear positive drug-sensitive pulmonary tuberculosis. Participants reverted to the standard treatment (RIFAFOUR e-275) once the study treatment (Day 1 to Day 14) was completed.
319 studies on the registry are indexed under Tuberculosis, Pulmonary; 71 are open to participants now.
This study's enrollment of 127 is below the median of 146 across 227 interventional studies indexed under Tuberculosis, Pulmonary.
Browse Tuberculosis, Pulmonary studies →GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
Compared within Tuberculosis, Pulmonary, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Tuberculosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants had:
Exclusion Criteria:
-infected participants who:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received GSK3036656 20 milligram (mg) + bedaquiline 400 mg once daily for 14 days; loading doses: 50 mg GSK3036656 (Day 1), 700 mg bedaquiline (Day 1), 500 mg (Day 2), then 400 mg daily (Days 3-14).
Drug: GSK3036656 · Drug: Bedaquiline
Participants received GSK3036656 20 mg + delamanid 300 mg once daily for 14 days; 50 mg GSK3036656 loading dose on Day 1.
Drug: GSK3036656 · Drug: Delamanid
Participants received delamanid 300 mg + bedaquiline 400 mg once daily for 14 days; bedaquiline loading doses: 700 mg (Day 1), 500 mg (Day 2), then 400 mg daily (Days 3-14).
Drug: Bedaquiline · Drug: Delamanid
Participants received Rifafour e-275 (or equivalent generic) once daily for 14 days.
Drug: RIFAFOUR e-275
Participants received GSK3036656 20 mg + BTZ-043 1000 mg once daily for 14 days; 50 mg GSK3036656 loading dose on Day 1.
Drug: GSK3036656 · Drug: BTZ-043
Participants received Rifafour e-275 (or equivalent generic) once daily for 14 days.
Drug: RIFAFOUR e-275
Participants received GSK3036656 20 mg + pretomanid 200 mg once daily for 14 days; 50 mg GSK3036656 loading dose on Day 1.
Drug: GSK3036656 · Drug: Pretomanid
Participants received GSK3036656 20 mg + linezolid 600 mg once daily for 14 days; 50 mg GSK3036656 loading dose on Day 1.
Drug: GSK3036656 · Drug: Linezolid
Participants received GSK3036656 20 mg + moxifloxacin 400 mg once daily for 14 days; 50 mg GSK3036656 loading dose on Day 1.
Drug: GSK3036656 · Drug: Moxifloxacin
Participants received Rifafour e-275 (or equivalent generic) once daily for 14 days.
Drug: RIFAFOUR e-275
GSK3036656 was administered.
Bedaquiline was administered.
Delamanid was administered.
Drug pages: Isoniazid · Rifampin · Pyrazinamide · Ethambutol
RIFAFOUR e-275 was administered.
BTZ-043 was administered.
Pretomanid was administered.
Linezolid was administered.
Moxifloxacin was administered.
Change From Baseline in log10 Colony Forming Units (CFU) of Mycobacterium Tuberculosis (MTB)
Baseline was defined as the mean of Day -2 and Day -1. If data was available at only one of these timepoints, then that value was used as baseline.
Time frame: At Baseline and at days 1, 2, 3, 4, 6, 8, 10, 12 and 14
Change From Baseline in Time to Sputum Culture Positivity
Baseline was defined as the mean of Day -2 and Day -1. If data was available at only one of these timepoints, then that value was used as baseline.
Time frame: At Baseline and at days 1, 2, 3, 4, 6, 8, 10, 12 and 14
Number of Participants With Serious Adverse Events (SAEs)
An SAE was defined as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, caused a congenital anomaly/birth defect, or was any other situation identified according to medical or scientific judgment.
Time frame: From Day 1 to Day 28
Number of Participants With Adverse Events (AE) of Grade 3 Severity or Higher
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not it was considered related to the study intervention. The intensity of AEs was assessed using the Division of Acquired Immunodeficiency Syndrome (DAIDS) criteria Version 2.1, where grades were defined based on numeric criteria as follows: Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: potentially life-threatening; Grade 5: death. A higher grade indicated greater severity. Any = occurrence of the event regardless of intensity grade.
Time frame: From Day 1 to Day 28
Number of Participants With Adverse Events Related to Study Treatment
Time frame: From Day 1 to Day 28
Number of Participants Withdrawn From the Treatment Due to Adverse Events
Time frame: From Day 1 to Day 28
Number of Participants Withdrawn From the Study Due to Adverse Events
Time frame: From Day 1 to Day 28
Number of Participants With Electrocardiogram (ECG) Values of Potential Clinical Importance (PCI)
PCI ECG values were defined as any ECG findings which, in the opinion of the investigator or medical monitor, would have interfered with the safety of the individual participant. The ECG measurements analyzed were PR Interval, QRS Duration, and QTcF Interval. A value was reported as "high" for a period if it had shifted from "low" or "within range" (W/in) at the start of the treatment period but was "high" during or at the end of the same treatment period. A value was reported as "low" for a period if it had shifted from "high" or "W/in" at the start of the treatment period but was "low" during or at the end of the same treatment period. A value was reported as "No Change" if it had remained unchanged (e.g., High to High), or as "To W/in Range" if it had been within range.
Time frame: From Day 1 to Day 28
Number of Participants With Hematology Laboratory Values of PCI
The analyzed hematology parameters were hematocrits, hemoglobin, lymphocytes, neutrophils, and platelets. A value was reported as "high" for a period if it had shifted from "low" or "within range" (W/in) at the start of the treatment period but was "high" during or at the end of the same treatment period. A value was reported as "low" for a period if it had shifted from "high" or "W/in" at the start of the treatment period but was "low" during or at the end of the same treatment period. A value was reported as "No Change" if it had remained unchanged (e.g., High to High), or as "To W/in Range" if it had been within range.
Time frame: From Day 1 to Day 28
Number of Participants With Clinical Chemistry Laboratory Values of PCI
The chemistry parameters analyzed were glucose, alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, calcium, creatinine, potassium, and sodium. A value was reported as "high" for a period if it had shifted from "low" or "within range" (W/in) at the start of the treatment period but was "high" during or at the end of the same treatment period. A value was reported as "low" for a period if it had shifted from "high" or "W/in" at the start of the treatment period but was "low" during or at the end of the same treatment period. A value was reported as "No Change" if it had remained unchanged (e.g., High to High), or as "To W/in Range" if it had been within range.
Time frame: From Day 1 to Day 28
Number of Participants With Vital Signs of PCI
The analyzed vital signs were systolic blood pressure, diastolic blood pressure, pulse rate. A value was reported as "high" for a period if it had shifted from "low" or "within range" (W/in) at the start of the treatment period but was "high" during or at the end of the same treatment period. A value was reported as "low" for a period if it had shifted from "high" or "W/in" at the start of the treatment period but was "low" during or at the end of the same treatment period. A value was reported as "No Change" if it had remained unchanged (e.g., High to High), or as "To W/in Range" if it had been within range.
Time frame: From Day 1 to Day 28
| Milestone | Standard of Care for Drug-sensitive Tuberculosis (DS - TB)_Cohort 1 | GSK3036656 + Bedaquiline | GSK3036656 + Delamanid | Delamanid + Bedaquiline | GSK3036656 + BTZ-043 | Standard of Care for DS - TB_Cohort 2 | GSK3036656 + Pretomanid | GSK3036656 + Linezolid | GSK3036656 + Moxifloxacin | Standard of Care for DS TB_Cohort 3 |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 9 | 14 | 15 | 16 | 14 | 3 | 16 | 13 | 14 | 11 |
| Completed | 9 | 14 | 15 | 16 | 13 | 3 | 16 | 12 | 13 | 10 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Participant reached protocol-defined stopping criteria | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Baseline was defined as the mean of Day -2 and Day -1. If data was available at only one of these timepoints, then that value was used as baseline.
| log10 CFU/milliliter (mL) | Standard of Care for Drug-sensitive Tuberculosis (DS - TB)_Cohort 1 | GSK3036656 + Bedaquiline | GSK3036656 + Delamanid | Delamanid + Bedaquiline | GSK3036656 + BTZ-043 | Standard of Care for DS-TB_Cohort 2 | GSK3036656 + Pretomanid | GSK3036656 + Linezolid | GSK3036656 + Moxifloxacin | Standard of Care for DS TB_Cohort 3 |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | 6.960 ± 1.1038 | 6.441 ± 1.0053 | 6.387 ± 0.9881 | 6.285 ± 0.7599 | 6.457 ± 1.0819 | 6.280 ± 1.1045 | 6.522 ± 0.7109 | 6.691 ± 0.6420 | 6.407 ± 0.4622 | 6.583 ± 0.5514 |
| Day 1 | -0.876 ± 0.7375 | -0.323 ± 0.6014 | 0.095 ± 0.4192 | -0.161 ± 0.4819 | 0.028 ± 0.3848 | -0.369 ± 0.3031 | -0.002 ± 0.5514 | -0.150 ± 0.3617 | -0.598 ± 1.0102 | -0.218 ± 0.7681 |
| Day 2 | -1.524 ± 0.5358 | -0.251 ± 0.6749 | -0.431 ± 1.2250 | -0.465 ± 0.8544 | -0.186 ± 0.6269 | -0.638 ± 0.4670 | -0.218 ± 0.7824 | -0.485 ± 0.7596 | -0.490 ± 0.3233 | -1.137 ± 0.3824 |
| Day 3 | -1.995 ± 1.0519 | -0.314 ± 0.7666 | -0.525 ± 0.4308 | -0.393 ± 0.7996 | -0.316 ± 0.5088 | -1.000 ± 0.4217 | -0.453 ± 0.6354 | -0.445 ± 0.6234 | -1.096 ± 0.9501 | -1.196 ± 0.6813 |
| Day 4 | -1.961 ± 0.6269 | -0.749 ± 0.6991 | -0.559 ± 0.9640 | -0.302 ± 0.8803 | -0.637 ± 0.5462 | -1.236 ± 0.6097 | -0.541 ± 0.6851 | -0.961 ± 0.7454 | -0.870 ± 0.5350 | -1.691 ± 0.0215 |
| Day 6 | -1.792 ± 0.2695 | -0.908 ± 1.0062 | -1.192 ± 0.6726 | -0.686 ± 0.8380 | -0.675 ± 0.8099 | -1.698 ± 0.8456 | -0.696 ± 0.6876 | -1.185 ± 0.5339 | -1.669 ± 1.3719 | -1.655 ± 1.0045 |
| Day 8 | -2.123 ± 0.9417 | -1.405 ± 0.6347 | -1.417 ± 0.8551 | -0.759 ± 0.8265 | -1.004 ± 0.7408 | -2.061 ± 1.0022 | -1.186 ± 0.5268 | -1.502 ± 0.4553 | -1.346 ± 0.5983 | -1.867 ± 0.8490 |
| Day 10 | -2.642 ± 0.4140 | -1.143 ± 0.8303 | -1.568 ± 0.7239 | -0.679 ± 0.7169 | -1.137 ± 0.6753 | -2.289 ± 1.9110 | -1.187 ± 0.7832 | -1.427 ± 0.8659 | -1.145 ± 0.5550 | -1.708 ± 1.2044 |
| Day 12 | -2.533 ± 0.5351 | -1.242 ± 1.0717 | -1.461 ± 0.5713 | -1.171 ± 1.0695 | -1.528 ± 1.1315 | -2.278 ± 1.7579 | -1.286 ± 0.5819 | -1.726 ± 0.8580 | -1.701 ± 0.9422 | -2.340 ± 1.4691 |
| Day 14 | -2.784 ± 0.6634 | -1.088 ± 0.5239 | -1.845 ± 0.7738 | -0.684 ± 1.1807 | -1.478 ± 0.8847 | -1.001 ± 1.2730 | -1.676 ± 0.7156 | -2.164 ± 1.4641 | -1.782 ± 0.7243 | -2.312 ± 1.2667 |
Baseline was defined as the mean of Day -2 and Day -1. If data was available at only one of these timepoints, then that value was used as baseline.
| log10 hours | Standard of Care for Drug-sensitive Tuberculosis (DS - TB)_Cohort 1 | GSK3036656 + Bedaquiline | GSK3036656 + Delamanid | Delamanid + Bedaquiline | GSK3036656 + BTZ-043 | Standard of Care for DS - TB_Cohort 2 | GSK3036656 + Pretomanid | GSK3036656 + Linezolid | GSK3036656 + Moxifloxacin | Standard of Care for DS TB_Cohort 3 |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | 1.987 ± 0.1350 | 2.016 ± 0.1253 | 2.039 ± 0.1316 | 2.057 ± 0.0947 | 2.077 ± 0.1713 | 2.079 ± 0.1144 | 2.000 ± 0.0936 | 2.002 ± 0.0798 | 2.023 ± 0.0819 | 2.002 ± 0.1120 |
| Day 1 | 0.143 ± 0.0868 | 0.077 ± 0.0799 | 0.009 ± 0.0525 | 0.037 ± 0.0505 | -0.004 ± 0.0989 | 0.098 ± 0.0716 | 0.010 ± 0.0394 | 0.030 ± 0.0472 | 0.079 ± 0.0847 | 0.082 ± 0.0749 |
| Day 2 | 0.243 ± 0.0487 | 0.172 ± 0.0637 | 0.096 ± 0.0700 | 0.089 ± 0.0614 | 0.041 ± 0.0972 | 0.167 ± 0.0528 | 0.089 ± 0.0894 | 0.078 ± 0.0731 | 0.139 ± 0.0761 | 0.199 ± 0.0975 |
| Day 3 | 0.266 ± 0.0706 | 0.222 ± 0.0757 | 0.129 ± 0.0690 | 0.170 ± 0.1878 | 0.053 ± 0.0676 | 0.197 ± 0.0298 | 0.122 ± 0.0730 | 0.121 ± 0.0686 | 0.153 ± 0.0574 | 0.212 ± 0.1004 |
| Day 4 | 0.320 ± 0.0847 | 0.234 ± 0.0584 | 0.182 ± 0.0685 | 0.142 ± 0.0616 | 0.093 ± 0.1009 | 0.232 ± 0.0895 | 0.160 ± 0.0544 | 0.140 ± 0.0634 | 0.181 ± 0.0955 | 0.211 ± 0.1102 |
| Day 6 | 0.344 ± 0.1012 | 0.295 ± 0.1063 | 0.234 ± 0.0665 | 0.165 ± 0.0919 | 0.125 ± 0.1005 | 0.302 ± 0.0654 | 0.187 ± 0.0486 | 0.183 ± 0.0990 | 0.237 ± 0.1791 | 0.289 ± 0.1049 |
| Day 8 | 0.364 ± 0.1425 | 0.327 ± 0.1044 | 0.234 ± 0.1165 | 0.236 ± 0.1915 | 0.180 ± 0.0967 | 0.210 ± 0.3165 | 0.215 ± 0.0772 | 0.251 ± 0.0779 | 0.267 ± 0.1073 | 0.340 ± 0.0968 |
| Day 10 | 0.401 ± 0.0951 | 0.367 ± 0.1011 | 0.279 ± 0.0749 | 0.223 ± 0.0649 | 0.215 ± 0.1119 | 0.299 ± 0.2348 | 0.276 ± 0.0722 | 0.242 ± 0.0976 | 0.286 ± 0.0951 | 0.292 ± 0.1206 |
| Day 12 | 0.361 ± 0.0424 | 0.389 ± 0.1344 | 0.294 ± 0.0748 | 0.290 ± 0.1459 | 0.232 ± 0.0907 | 0.337 ± 0.1660 | 0.287 ± 0.0708 | 0.317 ± 0.0991 | 0.251 ± 0.1546 | 0.355 ± 0.1764 |
| Day 14 | 0.434 ± 0.0714 | 0.376 ± 0.0938 | 0.328 ± 0.1019 | 0.330 ± 0.1773 | 0.273 ± 0.1296 | 0.258 ± 0.0591 | 0.344 ± 0.0729 | 0.267 ± 0.0955 | 0.323 ± 0.1045 | 0.362 ± 0.1319 |
An SAE was defined as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, caused a congenital anomaly/birth defect, or was any other situation identified according to medical or scientific judgment.
| Participants | Standard of Care for Drug-sensitive Tuberculosis (DS - TB)_Cohort 1 | GSK3036656 + Bedaquiline | GSK3036656 + Delamanid | Delamanid + Bedaquiline | GSK3036656 + BTZ-043 | Standard of Care for DS - TB_Cohort 2 | GSK3036656 + Pretomanid | GSK3036656 + Linezolid | GSK3036656 + Moxifloxacin | Standard of Care for DS - TB_Cohort 3 |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Serious Adverse Events (SAEs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not it was considered related to the study intervention. The intensity of AEs was assessed using the Division of Acquired Immunodeficiency Syndrome (DAIDS) criteria Version 2.1, where grades were defined based on numeric criteria as follows: Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: potentially life-threatening; Grade 5: death. A higher grade indicated greater severity. Any = occurrence of the event regardless of intensity grade.
| Participants | Standard of Care for Drug-sensitive Tuberculosis (DS - TB)_Cohort 1 | GSK3036656 + Bedaquiline | GSK3036656 + Delamanid | Delamanid + Bedaquiline | GSK3036656 + BTZ-043 | Standard of Care for DS - TB_Cohort 2 | GSK3036656 + Pretomanid | GSK3036656 + Linezolid | GSK3036656 + Moxifloxacin | Standard of Care for DS - TB_Cohort 3 |
|---|---|---|---|---|---|---|---|---|---|---|
| Grade 3 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Participants | Standard of Care for Drug-sensitive Tuberculosis (DS - TB)_Cohort 1 | GSK3036656 + Bedaquiline | GSK3036656 + Delamanid | Delamanid + Bedaquiline | GSK3036656 + BTZ-043 | Standard of Care for DS - TB_Cohort 2 | GSK3036656 + Pretomanid | GSK3036656 + Linezolid | GSK3036656 + Moxifloxacin | Standard of Care for DS - TB_Cohort 3 |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Adverse Events Related to Study Treatment | 5 | 4 | 5 | 6 | 7 | 1 | 3 | 4 | 7 | 6 |
| Participants | Standard of Care for Drug-sensitive Tuberculosis (DS - TB)_Cohort 1 | GSK3036656 + Bedaquiline | GSK3036656 + Delamanid | Delamanid + Bedaquiline | GSK3036656 + BTZ-043 | Standard of Care for DS TB_Cohort 2 | GSK3036656 + Pretomanid | GSK3036656 + Linezolid | GSK3036656 + Moxifloxacin | Standard of Care for DS TB_Coohrt 3 |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Withdrawn From the Treatment Due to Adverse Events | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 |
| Participants | Standard of Care for Drug-sensitive Tuberculosis (DS - TB)_Cohort 1 | GSK3036656 + Bedaquiline | GSK3036656 + Delamanid | Delamanid + Bedaquiline | GSK3036656 + BTZ-043 | Standard of Care for DS TB_Cohort 2 | GSK3036656 + Pretomanid | GSK3036656 + Linezolid | GSK3036656 + Moxifloxacin | Standard of Care for DS TB_Cohort 3 |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Withdrawn From the Study Due to Adverse Events | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
PCI ECG values were defined as any ECG findings which, in the opinion of the investigator or medical monitor, would have interfered with the safety of the individual participant. The ECG measurements analyzed were PR Interval, QRS Duration, and QTcF Interval. A value was reported as "high" for a period if it had shifted from "low" or "within range" (W/in) at the start of the treatment period but was "high" during or at the end of the same treatment period. A value was reported as "low" for a period if it had shifted from "high" or "W/in" at the start of the treatment period but was "low" during or at the end of the same treatment period. A value was reported as "No Change" if it had remained unchanged (e.g., High to High), or as "To W/in Range" if it had been within range.
| Participants | Standard of Care for Drug-sensitive Tuberculosis (DS - TB)_Cohort 1 | GSK3036656 + Bedaquiline | GSK3036656 + Delamanid | Delamanid + Bedaquiline | GSK3036656 + BTZ-043 | Standard of Care for DS TB_Cohort 2 | GSK3036656 + Pretomanid | GSK3036656 + Linezolid | GSK3036656 + Moxifloxacin | Standard of Care for DS TB_Cohort 3 |
|---|---|---|---|---|---|---|---|---|---|---|
| PR Interval, To Low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PR Interval, To W/in Range or No Change | 9 | 13 | 15 | 16 | 14 | 3 | 16 | 13 | 12 | 11 |
| PR Interval, To High | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| QRS Duration, To Low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| QRS Duration, To W/in Range or No Change | 9 | 14 | 14 | 16 | 14 | 3 | 16 | 13 | 13 | 11 |
| QRS Duration, To High | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| QTcF Interval, To Low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| QTcF Interval, To W/in Range or No Change | 9 | 14 | 13 | 14 | 14 | 3 | 15 | 11 | 14 | 11 |
| QTcF Interval, To High | 0 | 0 | 2 | 2 | 0 | 0 | 1 | 2 | 0 | 0 |
The analyzed hematology parameters were hematocrits, hemoglobin, lymphocytes, neutrophils, and platelets. A value was reported as "high" for a period if it had shifted from "low" or "within range" (W/in) at the start of the treatment period but was "high" during or at the end of the same treatment period. A value was reported as "low" for a period if it had shifted from "high" or "W/in" at the start of the treatment period but was "low" during or at the end of the same treatment period. A value was reported as "No Change" if it had remained unchanged (e.g., High to High), or as "To W/in Range" if it had been within range.
| Participants | Standard of Care for Drug-sensitive Tuberculosis (DS - TB)_Cohort 1 | GSK3036656 + Bedaquiline | GSK3036656 + Delamanid | Delamanid + Bedaquiline | GSK3036656 + BTZ-043 | Standard of Care for DS TB_Cohort 2 | GSK3036656 + Pretomanid | GSK3036656 + Linezolid | GSK3036656 + Moxifloxacin | Standard of Care for DS TB_Cohort 3 |
|---|---|---|---|---|---|---|---|---|---|---|
| Hematocrit, To Low | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hematocrit, To W/in Range or No Change | 9 | 14 | 15 | 15 | 14 | 3 | 16 | 13 | 14 | 11 |
| Hematocrit, To High | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin, To Low | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin, To W/in Range or No Change | 9 | 14 | 14 | 16 | 14 | 3 | 16 | 13 | 14 | 11 |
| Hemoglobin, To High | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes, To Low | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 2 | 0 | 0 |
| Lymphocytes, To W/in Range or No Change | 9 | 14 | 14 | 16 | 13 | 3 | 15 | 11 | 14 | 11 |
| Lymphocytes, To High | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophils, To Low | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophils, To W/in Range or No Change | 9 | 14 | 14 | 16 | 14 | 3 | 16 | 13 | 14 | 11 |
| Neutrophils, To High | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets, To Low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets, To W/in Range or No Change | 8 | 14 | 12 | 12 | 12 | 3 | 13 | 10 | 13 | 11 |
| Platelets, To High | 1 | 0 | 3 | 4 | 2 | 0 | 3 | 3 | 1 | 0 |
The chemistry parameters analyzed were glucose, alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, calcium, creatinine, potassium, and sodium. A value was reported as "high" for a period if it had shifted from "low" or "within range" (W/in) at the start of the treatment period but was "high" during or at the end of the same treatment period. A value was reported as "low" for a period if it had shifted from "high" or "W/in" at the start of the treatment period but was "low" during or at the end of the same treatment period. A value was reported as "No Change" if it had remained unchanged (e.g., High to High), or as "To W/in Range" if it had been within range.
| Participants | Standard of Care for Drug-sensitive Tuberculosis (DS - TB)_Cohort 1 | GSK3036656 + Bedaquiline | GSK3036656 + Delamanid | Delamanid + Bedaquiline | GSK3036656 + BTZ-043 | Standard of Care for DS - TB_Cohort 2 | GSK3036656 + Pretomanid | GSK3036656 + Linezolid | GSK3036656 + Moxifloxacin | Standard of Care for DS - TB_Cohort 3 |
|---|---|---|---|---|---|---|---|---|---|---|
| Glucose, To Low | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Glucose, To W/in Range or No Change | 8 | 14 | 15 | 16 | 14 | 3 | 15 | 12 | 14 | 11 |
| Glucose, To High | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| ALT, To Low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT, To W/in Range or No Change | 9 | 14 | 14 | 16 | 14 | 3 | 15 | 13 | 12 | 11 |
| ALT, To High | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 2 | 0 |
| AST, To Low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST, To W/in Range or No Change | 9 | 14 | 15 | 16 | 14 | 3 | 16 | 12 | 14 | 11 |
| AST, To High | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Bilirubin, To Low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bilirubin, To W/in Range or No Change | 9 | 14 | 15 | 16 | 14 | 3 | 16 | 13 | 14 | 11 |
| Bilirubin, To High | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Calcium, To Low | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Calcium, To W/in Range or No Change | 9 | 13 | 15 | 16 | 14 | 3 | 16 | 13 | 14 | 11 |
| Calcium, To High | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine, To Low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine, To W/in Range or No Change | 8 | 14 | 13 | 16 | 11 | 2 | 15 | 12 | 14 | 10 |
| Creatinine, To High | 1 | 0 | 2 | 0 | 3 | 1 | 1 | 1 | 0 | 1 |
| Potassium, To Low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Potassium, To W/in Range or No Change | 8 | 13 | 13 | 13 | 12 | 3 | 14 | 11 | 13 | 11 |
| Potassium, To High | 1 | 1 | 2 | 3 | 2 | 0 | 2 | 2 | 1 | 0 |
| Sodium, To Low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sodium, To W/in Range or No Change | 9 | 14 | 15 | 16 | 14 | 3 | 16 | 13 | 14 | 11 |
| Sodium, To High | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The analyzed vital signs were systolic blood pressure, diastolic blood pressure, pulse rate. A value was reported as "high" for a period if it had shifted from "low" or "within range" (W/in) at the start of the treatment period but was "high" during or at the end of the same treatment period. A value was reported as "low" for a period if it had shifted from "high" or "W/in" at the start of the treatment period but was "low" during or at the end of the same treatment period. A value was reported as "No Change" if it had remained unchanged (e.g., High to High), or as "To W/in Range" if it had been within range.
| Participants | Standard of Care for Drug-sensitive Tuberculosis (DS - TB)_Cohort 1 | GSK3036656 + Bedaquiline | GSK3036656 + Delamanid | Delamanid + Bedaquiline | GSK3036656 + BTZ-043 | Standard of Care for DS - TB_Cohort 2 | GSK3036656 + Pretomanid | GSK3036656 + Linezolid | GSK3036656 + Moxifloxacin | Standard of Care for DS TB_Cohort 3 |
|---|---|---|---|---|---|---|---|---|---|---|
| Systolic Blood Pressure, To Low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Systolic Blood Pressure, To W/in Range or No Change | 9 | 14 | 15 | 16 | 14 | 3 | 16 | 13 | 14 | 11 |
| Systolic Blood Pressure, To High | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Diastolic Blood Pressure, To Low | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Diastolic Blood Pressure, To W/in Range or No Change | 9 | 14 | 15 | 16 | 12 | 3 | 16 | 13 | 14 | 11 |
| Diastolic Blood Pressure, To High | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Pulse Rate, To Low | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pulse Rate, To W/in Range or No Change | 9 | 14 | 14 | 15 | 9 | 3 | 16 | 12 | 12 | 10 |
| Pulse Rate, To High | 0 | 0 | 1 | 1 | 5 | 0 | 0 | 1 | 2 | 1 |
Collected over Adverse events and serious AEs were reported from Day 1 to Day 28. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Standard of Care for Drug-sensitive Tuberculosis (DS - TB)_Cohort 1 | 0/9 (0%) | 0/9 (0%) | 9/9 (100%) |
| GSK3036656 + Bedaquiline | 0/14 (0%) | 0/14 (0%) | 11/14 (78.6%) |
| GSK3036656 + Delamanid | 0/15 (0%) | 0/15 (0%) | 10/15 (66.7%) |
| Delamanid + Bedaquiline | 0/16 (0%) | 0/16 (0%) | 12/16 (75%) |
| GSK3036656 + BTZ-043 | 0/14 (0%) | 0/14 (0%) | 11/14 (78.6%) |
| Standard of Care for DS - TB_Cohort 2 | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| GSK3036656 + Pretomanid | 0/16 (0%) | 0/16 (0%) | 12/16 (75%) |
| GSK3036656 + Linezolid | 0/13 (0%) | 1/13 (7.7%) | 8/13 (61.5%) |
| GSK3036656 + Moxifloxacin | 0/14 (0%) | 0/14 (0%) | 11/14 (78.6%) |
| Standard of Care for DS TB_Cohort 3 | 0/11 (0%) | 0/11 (0%) | 9/11 (81.8%) |
| Event | Standard of Care for Drug-sensitive Tuberculosis (DS - TB)_Cohort 1 | GSK3036656 + Bedaquiline | GSK3036656 + Delamanid | Delamanid + Bedaquiline | GSK3036656 + BTZ-043 | Standard of Care for DS - TB_Cohort 2 | GSK3036656 + Pretomanid | GSK3036656 + Linezolid | GSK3036656 + Moxifloxacin | Standard of Care for DS TB_Cohort 3 |
|---|---|---|---|---|---|---|---|---|---|---|
| SeizureNervous system disorders | 0/9 | 0/14 | 0/15 | 0/16 | 0/14 | 0/3 | 0/16 | 1/13 | 0/14 | 0/11 |
| Event | Standard of Care for Drug-sensitive Tuberculosis (DS - TB)_Cohort 1 | GSK3036656 + Bedaquiline | GSK3036656 + Delamanid | Delamanid + Bedaquiline | GSK3036656 + BTZ-043 | Standard of Care for DS - TB_Cohort 2 | GSK3036656 + Pretomanid | GSK3036656 + Linezolid | GSK3036656 + Moxifloxacin | Standard of Care for DS TB_Cohort 3 |
|---|---|---|---|---|---|---|---|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | 4/9 | 2/14 | 1/15 | 4/16 | 1/14 | 1/3 | 0/16 | 1/13 | 0/14 | 2/11 |
| Abdominal painGastrointestinal disorders | 0/9 | 1/14 | 0/15 | 0/16 | 0/14 | 1/3 | 1/16 | 0/13 | 1/14 | 0/11 |
| Neck painMusculoskeletal and connective tissue disorders | 0/9 | 0/14 | 0/15 | 0/16 | 0/14 | 1/3 | 0/16 | 0/13 | 0/14 | 0/11 |
| HeadacheNervous system disorders | 3/9 | 2/14 | 0/15 | 2/16 | 3/14 | 0/3 | 0/16 | 0/13 | 0/14 | 1/11 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 2/9 | 1/14 | 1/15 | 0/16 | 0/14 | 1/3 | 2/16 | 0/13 | 1/14 | 1/11 |
| Rash pruriticSkin and subcutaneous tissue disorders | 1/9 | 1/14 | 2/15 | 0/16 | 0/14 | 1/3 | 1/16 | 0/13 | 0/14 | 2/11 |
| NauseaGastrointestinal disorders | 2/9 | 3/14 | 3/15 | 2/16 | 2/14 | 0/3 | 1/16 | 2/13 | 1/14 | 1/11 |
| Back painMusculoskeletal and connective tissue disorders | 2/9 | 0/14 | 3/15 | 2/16 | 2/14 | 0/3 | 0/16 | 0/13 | 1/14 | 0/11 |
| Gamma-glutamyltransferase increasedInvestigations | 0/9 | 0/14 | 0/15 | 0/16 | 0/14 | 0/3 | 1/16 | 0/13 | 3/14 | 0/11 |
| DizzinessNervous system disorders | 0/9 | 0/14 | 0/15 | 2/16 | 3/14 | 0/3 | 0/16 | 0/13 | 2/14 | 1/11 |
| Age, Continuous(YEARS) | Standard of Care for Drug-sensitive Tuberculosis (DS - TB)_Cohort 1 | GSK3036656 + Bedaquiline | GSK3036656 + Delamanid | Delamanid + Bedaquiline | GSK3036656 + BTZ-043 | Standard of Care for DS - TB_Cohort 2 | GSK3036656 + Pretomanid | GSK3036656 + Linezolid | GSK3036656 + Moxifloxacin | Standard of Care for DS TB_Cohort 3 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 33.3 ± 7.79 | 31.5 ± 8.70 | 32.9 ± 9.01 | 33.1 ± 7.49 | 33.9 ± 7.37 | 46.3 ± 10.12 | 35.4 ± 11.02 | 36.1 ± 12.15 | 31.6 ± 7.80 | 34.6 ± 11.33 | 33.9 ± 9.32 |
| Sex: Female, Male(Participants) | Standard of Care for Drug-sensitive Tuberculosis (DS - TB)_Cohort 1 | GSK3036656 + Bedaquiline | GSK3036656 + Delamanid | Delamanid + Bedaquiline | GSK3036656 + BTZ-043 | Standard of Care for DS - TB_Cohort 2 | GSK3036656 + Pretomanid | GSK3036656 + Linezolid | GSK3036656 + Moxifloxacin | Standard of Care for DS TB_Cohort 3 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 2 | 1 | 3 | 0 | 0 | 1 | 1 | 2 | 2 | 13 |
| Male | 8 | 12 | 14 | 13 | 14 | 3 | 15 | 12 | 12 | 9 | 112 |
| Race/Ethnicity, Customized(Participants) | Standard of Care for Drug-sensitive Tuberculosis (DS - TB)_Cohort 1 | GSK3036656 + Bedaquiline | GSK3036656 + Delamanid | Delamanid + Bedaquiline | GSK3036656 + BTZ-043 | Standard of Care for DS - TB_Cohort 2 | GSK3036656 + Pretomanid | GSK3036656 + Linezolid | GSK3036656 + Moxifloxacin | Standard of Care for DS TB_Cohort 3 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASIAN | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| BLACK OR AFRICAN AMERICAN | 9 | 13 | 15 | 16 | 14 | 3 | 16 | 13 | 14 | 11 | 124 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Ran from Jul 2022 to primary completion in May 2025, 34 months.
Results were first posted in Jun 2026, 1 year after primary completion.
Of 43 phase 2 interventional studies under Tuberculosis, Pulmonary, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 37. This study's 34 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: GSK656 · Bedaquiline · OPC-67683 · Isoniazid · Rifampin · Pyrazinamide · Ethambutol